Skip to main navigation Skip to search Skip to main content

Splicing Deregulation and Splicing Modulation in Acute Myeloid Leukemia: DNA is not Destiny

  • IM van der Werf

Research output: PhD ThesisPhd-Thesis - Research and graduation internal

Abstract

Cancer is thought to arise from accumulation of DNA mutations. However, AML is a heterogeneous disease characterized by diverse mutations each occurring at low frequencies. Actually, AML is a subtype with a relatively low mutational load compared to other cancer types. In addition, in children, DNA is far less damaged by exposure or age. Thus, also AML might not only be driven by differences in genomic content but also by transcriptomic heterogeneity. In this thesis we aimed to study deregulated splicing in AML and uncover its role in leukemogenesis.
Original languageEnglish
QualificationDoctor of Philosophy
Awarding Institution
  • Vrije Universiteit Amsterdam
Supervisors/Advisors
  • Kaspers, Gertjan, Supervisor
  • Cloos, Jacqueline, Supervisor
  • Wojtuszkiewicz, Anna, Co-supervisor
  • Groen, Richard, Co-supervisor
Thesis sponsors
Award date1 Feb 2022
Publication statusPublished - 1 Feb 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Alternative Splicing
  • Splicing Modulation
  • Splicing Deregulation
  • Splicing Factor Mutation
  • SF3B1
  • FLT3/ITD
  • Acute Myeloid Leukemia
  • pediatric acute myeloid leukemia

Fingerprint

Dive into the research topics of 'Splicing Deregulation and Splicing Modulation in Acute Myeloid Leukemia: DNA is not Destiny'. Together they form a unique fingerprint.

Cite this